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ABSTRACT 
Cardiac inflammatory response after myocardial infarction (MI) is essential to 
clear necrotic myocardium for cardiac healing, while excessive and prolonged 
inflammation extends the infarction and promotes adverse cardiac remodeling. NF-κB is 
the pivot regulator upstream of inflammatory response. Overaction of NF-κB exaggerates 
inflammation and contributes to detrimental outcomes of MI as well as other inflammatory 
diseases. 
Here we report RhoE as a negative inflammatory mediator by specifically 
inhibiting NF-κB. RhoE-deficient mice show overactivation of NF-κB in heart and 
develop excessive inflammation after MI. Mechanistically, RhoE interacts with p65 and 
p50 in cytosol and inhibits their nuclear translocation. RhoE also occupies the 
dimerization domain of p65 to impede the formation of p65/p50 heterodimer. Finally, we 
show that cardiac-specific RhoE overexpression restrains post-MI inflammation and 
improves cardiac function and survival. These findings identify RhoE as an important 
mediator of NF-κB-induced inflammation, and therefore, RhoE may serve as a potential 
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NOMENCLATURE 
RhoE Rho family GTPase 3 
MI Myocardial infarction 
AMI Acute myocardial infarction 
CAD Coronary artery disease 
HF Heart failure 
HCM Hypertrophic cardiomyopathy 
TAC Transverse aortic constriction 
VEGF Vascular endothelial growth factor 
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells 
IκBα Nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor, alpha 
IKK IκB kinase 
Ly-6G Lymphocyte antigen 6G 
F4/80 Adhesion G protein-coupled receptor E1 
TNF Tumor necrosis factor 
MMPs Matrix metalloproteinases 
EMSA Electrophoretic mobility shift assay 
BiFC Bimolecular fluorescent complementation 
VN N-terminus of fluorescent protein Venus 
VC C-terminus of fluorescent protein Venus 
vii 
NTD N-terminal domain 
DD Dimerization domain 
TAD Transactivation domain 
ROCK1 Rho-associated coiled-coil-containing protein kinase 1 
NLS Nuclear localization signal 
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I.1 Myocardial Infarction (MI) 
 
Myocardial infarction (MI), commonly known as heart attack, is a severe cardiac ischemic 
disease caused by coronary artery thrombotic occlusion1. Based on the 2016 report of 
American Heart Association, there are about 550,000 Americans newly suffering from 
myocardial infarction (defined as first hospitalized myocardial infarction) and 200,000 
recurrent cases2. Most cases of MI occur due to coronary artery disease (CAD) and 
conventional risk factors of MI include cigarette smoking, high blood cholesterol, high 
blood pressure, diabetes and obesity.  
 The healing process of the infarcted heart following MI can be divided into three 
distinct, but overlapping phases, including the inflammatory phase, the proliferative phase, 




Table 1 The healing stages after myocardial infarction.  
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 During the inflammatory phase, dying cardiomyocytes-released alarmins activate 
innate immune signaling to induce the secretion of pro-inflammatory chemokines and 
cytokines4. Among those pro-inflammatory factors, IL-1 signaling plays a central role in 
recruiting leukocytes (neutrophils and macrophages) to further promote chemokines and 
cytokines expression5. The leukocytes are then recruited to the infarcted area to 
phagocytose dead cardiomyocytes and matrix debris. However, excessive inflammation 
could cause inflammatory injuries and extend the infarct area. The inflammatory phase 
normally lasts about one week after myocardial infarction, and apoptosis of the infiltrated 
neutrophils and the resolution of the acute inflammation marks the end of this phase3. 
Following the inflammatory phase, anti-inflammatory monocyte subpopulations and 
regulatory T cells become the predominant cell types in the infarct area to suppress 
inflammation. More importantly, cardiac monocytes differentiate towards anti-
inflammatory subtype (M2 macrophage subtype) instead of pro-inflammatory subtype 
(M1 macrophage subtype), which effectively contribute to the subsequent reparative 
processes6. The inflammatory phase is most dangerous phase because most myocardial 
infarction death occurs in this phase. 
 During the proliferative phase of cardiac healing, activated myofibroblasts become 
the predominant cell type in the healing region7. These myofibroblasts are dissimilar from 
typical myofibroblasts in that they are phenotypically modulated fibroblasts that 
synthesize large amount of structural and matricellular extracellular matrix proteins 
instead of expressing smooth muscle cell-specific proteins8. Activated myoblasts migrate 
into the border zone of the infarct area, where they secrete the collagen and extracellular 
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matrix proteins to initiate the scar formation. Deposition of these structural matrix proteins 
into the infarct area preserves the ventricular integrity and geometry to prevent aneurysm 
and cardiac rupture. However, extracellular matrix deposition at remote sites from the 
infarct area can lead to excessive cardiac fibrosis and ventricular stiffness, which is an 
inevitable process that leads to adverse cardiac remodeling and constitutes the basis of the 
development of heart failure8. The proliferative phase usually ends in the first month after 
myocardial infarction. The maturation phase following the proliferative phase lasts more 
than two months to enable complete formation of a mature cross-linked scar. The 
infiltration of myofibroblasts into the infarct area is suppressed and the activated 
myofibroblasts are induced to apoptosis to end the proliferative activity in the scar. The 
collagenous matrix is cross-linked to form a mature scar. Thus, the lost myocardium is 







I.2 Inflammatory Response and Post-MI Inflammation 
 
Inflammation is the biological responses of the body tissues to injurious stimuli, such as 
physical tissue damages, infection by pathogens, and toxins9. Inflammation can be 
classified as either acute inflammation or chronic inflammation based on the causative 
agent, major cells involved, primary mediators, and duration10. Acute inflammation occurs 
immediately after the tissue damages. Danger signals released from the injured tissues 
activate innate immune pathways to induce pro-inflammatory factors synthesis and 
secretion, and promote the expression of adhesion molecules on vascular endothelium. 
Chemokines and cytokines then recruit the leukocytes from the blood vessels into the 
injured tissues, which propagate and expand the inflammatory response. If the 
inflammation is no longer needed, the inflammatory response must be actively terminated 
through a process called “resolution of inflammation”. If the inflammation is unresolved 
and prolonged, acute inflammation switches to chronic inflammation status, which is 
characterized by simultaneous destruction and healing of the tissue9. 
 Dysregulated inflammatory response contributes to many pathological changes 
and human diseases. Together with immune system, inflammatory abnormality has been 
involved in allergic reactions, myopathies, autoimmune diseases and autoinflammatory 
diseases11-13. Moreover, inflammatory disorders have been proved to play essential roles 
in the pathogenesis of cancer, AIDS, atherosclerosis, hypertrophic cardiomyopathy 
(HCM), and ischemic cardiomyopathy14-17.  
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 Post-MI inflammation plays an important role in the healing and remodeling of the 
infarcted heart3, 18. During the inflammatory phase, acute inflammation is developed and 
large amounts of pro-inflammatory chemokines and cytokines are released, which recruit 
leukocyte infiltration into the infarct area. Infiltrated leukocytes, especially macrophages, 
actively clear the necrotic cardiomyocytes and extracellular matrix debris through 
phagocytosis. The inflammation then is suppressed and the healing process proceeds to 
the next stage. Thus, acute inflammation is a prerequisite for the repairing of the infarct 
myocardium. However, dysregulated post-infarction inflammation is detrimental. 
Overactivated inflammation leads to extra loss of myocardium and causes inflammatory 
injury in the inflammatory phase, resulting in extended ischemic injury and enlarged 
infarct size. Moreover, prolonged inflammation abates the activation of myofibroblasts 
and thus delays the proliferative phase. The infarct myocardium cannot be repaired timely, 
and the integrity and geometry of the ventricle cannot be maintained, which promotes the 




I.3 Anti-inflammation Therapeutics in Myocardial Infarction 
 
Based on the deleterious effects of excessive inflammation to the cardiac healing after 
myocardial infarction, multiple anti-inflammatory therapeutic strategies have been tested, 
aiming to attenuate the inflammatory injuries. These strategies can be divided into three 
categories: 1) enhancement of anti-inflammatory pathways; 2) inhibition of pro-
inflammatory pathways; 3) shifting the balance from pro-inflammatory to reparative 
myeloid cell subsets4, 19. 
 There are several endogenous mechanisms exist that tightly control the 
inflammation after myocardial infarction. The expression levels of these endogenous 
inflammatory inhibitors are upregulated during the processes of resolving inflammation 
in the inflammatory phase. Interleukin 10 (IL-10) is a pleiotropic anti-inflammatory 
cytokine that is primarily secreted by the infiltrated macrophages after myocardial 
infarction20. IL-10 suppresses inflammatory response by inhibiting the expression of pro-
inflammatory cytokines, such as TNFα and IL-1β21, 22. A recent study showed that IL-10 
also protects the infarcted heart from adverse cardiac remodeling by stimulating M2 
subtype macrophage polarization23. Transforming growth factor β (TGF-β) is another 
pleiotropic cytokine that negatively mediates post-infarction inflammatory response. In 
the end stage of the inflammatory phase, the expression of TGF-β is upregulated to drive 
the differentiation of fibroblast to myofibroblast24 . Inhibition of TGF-β signaling prolongs 
the inflammation and deteriorates the cardiac contractile function in the mouse myocardial 
infarction model25.  
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Another anti-inflammatory strategy is the inhibition of pro-inflammatory 
pathways. Here, suppressions of two pro-inflammatory factors are introduced. The first 
one is chemokine (C-C motif) ligand 2 (CCL2). CCL2 is a chemoattractant protein that 
recruits monocyte/macrophage during myocardial infarction26. Gene therapy with an 
antagonistic CCL2 mutant suppresses the recruitment of macrophages into the infarct area, 
resulting in improved ventricular remodeling and survival after myocardial infarction27. 
The other pro-inflammatory factor is toll-like receptor 4 (TLR4), which is the specific 
receptor for danger-associated molecular patterns (DAMPs). TLR4-mediated recruitment 
of leukocytes is a critical step for the infiltration of leukocytes into the infarcted heart. 
Genetic ablation of TLR4 in mice showed diminished leukocyte recruitment and reduced 
pro-inflammatory cytokine expression after myocardial infarction28.  
The third anti-inflammatory strategy is to shift the balance of myeloid cells from 
pro-inflammatory subsets to reparative subsets. In the healing process of myocardial 
infarction, there are two subsets of monocyte existed in the infarct area: M1 subset 
monocytes that dominate on days 1 to 4; and M2 subset monocytes that dominate on days 
5 to 1029. M1 subset monocytes are responsible for clearing necrotic cardiomyocytes and 
matrix debris by phagocytosis, and further promoting the inflammatory response by 
expressing pro-inflammatory factors, such as TNFα, IL-1β and MMPs. On the contrary, 
M2 subset monocytes contribute in resolving the inflammation by expressing IL-10 and 
TGF-β. M2 subset monocytes propagate the healing process and promote angiogenesis by 
secreting vascular endothelial growth factor (VEGF)6, 30, 31. Thus, shifting the monocytes 
from M1 subset to M2 subset may avoid excessive digestion of the infarcted myocardium 
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and promote the reparative process. Phosphatidylserine-presenting liposomes have shown 
the ability to induce M2 monocyte subset32. Mice treated with phosphatidylserine-
presenting liposomes showed significantly decreased infarct size, increased angiogenesis, 
and improved cardiac functions after myocardial infarction. 
 Clinically, some anti-inflammatory strategies have been eventually tested in MI 
patients. However, most of these strategies failed to prove the same promising outcomes 
as in the experimental animal studies. Here, anti-inflammatory clinical trials of 
glucocorticoids, nonsteroidal anti-inflammatory drugs, integrins, metalloproteinases, and 
cytokines will be introduced. 
 Glucocorticoids (GCs) are a class of steroid hormones. Glucocorticoids are 
clinically used to suppress various allergic, inflammatory, and autoimmune disorders33. 
Glucocorticoids inhibit inflammation through three mechanisms: transcriptionally 
modifying the expression of inflammatory genes via glucocorticoid-responsive element; 
inhibiting NF-κB activation via cortisol-glucocorticoid receptor complex; activating 
endothelial nitric oxide synthase via membrane-associated receptors. However, clinical 
trials failed to show beneficial effects of glucocorticoids in patients with myocardial 
infarction34. Current clinical guidelines for AMI patients are recommend against the 
treatment of glucocorticoids. 
 Nonsteroidal anti-inflammatory drugs (NSAIDs) also broadly suppress 
inflammation. NSAIDs inhibit the activity of cyclooxygenase-2 (COX 2) to reduce 
prostanoid production from arachidonic acid35. Unfortunately, clinical treatment with 
NSAIDs in AMI patients exacerbates the outcomes of acute myocardial infarction36. 
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Moreover, a recent observational study showed that the use of NSAIDs in non-AMI 
patients is associated with an increased risk of acute myocardial infarction37, 38. 
Collectively, NSAIDs are not recommended to be used in the treatment of myocardial 
infarction. 
  Integrins are endothelial adhesion molecules that help the activated neutrophils to 
migrate from the blood vessels into the infarcted myocardium. Antibodies against these 
endothelial adhesion molecules are proved to be beneficial in animal MI studies39, 40, 
however, outcomes of the related clinical trials are conflicting. In LIMIT-AMI (limitation 
of myocardial infarction following thrombolysis in acute myocardial infarction) clinical 
trial, AMI patients treated with a monoclonal antibody against CD18 did not show 
diminished AMI injury41. Moreover, in the HALT-AMI clinical trial, the treatment with a 
recombinant antibody against CD11/CD18 also failed to show beneficial effects to AMI 
patients42. One possible explanation for these negative results is that the endothelial cell 
barrier in the heart vessels has been irreversible damaged during the myocardial infarction 
and thus the efficacy of the antibody is undermined to suppress the recruitment of 
leukocytes22.  
 Metalloproteinases (MMPs) function in degrading extracellular matrix and 
collagen43. Increased activity of MMPs in the inflammatory phases contributes to cardiac 
aneurysm and even ventricular rupture in the infarcted ventricular wall. Overactivation of 
MMPs also leads to collagen-scar thinning, resulting in ventricular dilation. Several 
inhibitors on MMPs have been tested in the clinical trials. PG-116800, an inhibitor for 
MMP-2, -3, -8, -9, -13, and -14, however, failed to improve adverse ventricular 
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remodeling at six months after myocardial infarction in the phase II RCT PREMIER 
(prevention of myocardial infarction early remodeling) clinical trial44. On the contrary, 
doxycycline, another MMP inhibitor, showed beneficial effects in the phase II TIPTOP 
(early short-term doxycycline therapy in patients with acute myocardial infarction and left 
ventricular dysfunction to prevent the ominous progression to adverse remodeling) clinical 
trial45. Doxycycline significantly reduces the degree of ventricular dilation and the major 
adverse cardiac events at six months after myocardial infarction. 
 Anti-pro-inflammatory cytokines is another strategy to diminish the inflammatory 
injury in myocardial infarction. IL-1β, one major pro-inflammatory cytokine, activates 
NF-κB signaling via interaction with myeloid differentiation factor 88 and the downstream 
IL-1 receptor-associated kinase type 446. IL-1 blockade has showed improved cardiac 
remodeling and cardiac function in the animal AMI models47-49. Clinical trials also proved 
the beneficial effects of IL-1 blockade. In the phase II VCU-ART (Virginia 
Commonwealth University acute remodeling trial) and VCU-ART2 trials, AMI patients 
treated with anakinra, a soluble IL-1 receptor acting to trap the circulating IL-1, tend to 
show improved ventricular remodeling and reduced heart failure incidence at three months 
after myocardial infarction50, 51. TNFα is another important pro-inflammatory cytokine 
that associates with cell death and inflammation. However, in a recent clinical trial, 
etanercept, a specific TNFα trapper, failed to provide beneficial effects to AMI patients52. 
Together with the disappointing results from TNFα blockers in HF patients53, TNFα-
blocking drugs are not recommended for patients with cardiovascular diseases. 
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 Collectively, the major anti-inflammatory therapeutics have been introduced as 
above. Most of the clinical trials failed to prove the similar beneficial effects of anti-
inflammatory therapeutics in the animal studies. The disappointing results of these 
translational studies may be high due to the following reasons: 1) experimental animals 
significantly differ from humans; 2) surgical ligation of the coronary artery to induce 
myocardial infarction in animals is largely different from the process of atherothrombosis-
induced coronary artery narrowing in human; 3) the variance of post-AMI inflammatory 
status is more complex in human than in the experimental animals. Therefore, more 
studies need to be performed to clearly understand the complexity of the inflammation 
during myocardial infarction. Also, novel mechanisms are required to provide new 




I.4 NF-κB Signaling 
 
I.4.1 Structure of the NF-κB family 
 
Transcription factor NF-κB controls the expression of many genes involved in a broad 
range of biological processes54, 55. This part will introduce the members and their structure 
of the NF-κB family, the regulation of NF-κB signaling, and the clinical significance of 
dysregulated NF-κB signaling. 
 NF-κB was first discovered as a DNA binding protein complex in the nuclei of 
activated B lymphocytes about thirty years ago56. Further studies revealed that the NF-κB 
complex is composed of 5 different subunits that contain a conserved amino sequence in 
the amino-terminal end termed Rel homology region (RHR) (Fig. 1). The Rel homology 
region contains two function domains, the amino-terminal domain (NTD) that is 
responsible for DNA binding activity; and the dimerization domain (DD) that mediates 
the homo- and hetero-dimerization of the NF-κB subunits. Based on their structure and 
functional domains, these 5 subunits are further divided into two classes: class I includes 
p50 and p52; class II includes p65, c-Rel and RelB. The carboxy-terminus of class I 
proteins contains glycine-rich regions and has transrepression activity, while class II 








Figure 1. Schematic structure of the NF-κB family subunits. 
There are five subunits in the human NF-κB family. Each subunit contains the Rel 
homology region (RHR) in the amino-terminal end. The Rel homology region contains 
two functional domains: amino-terminal domain (NTD) and dimerization domain (DD). 
Two of the subunits, p50 and p52, contain a glycine-rich region in the carboxy-terminal 
end, which has transrepression activity. The other three subunits, p65, c-Rel and RelB, 
contain a transactivation domain (TAD) in the carboxy-terminal end, which has 
transactivation activity. RelB also contains a predicted leucine zipper motif (LZ) in its 
amino-terminal end, which is essential to RelB transcriptional activity. 
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I.4.2 NF-κB dimerization 
 
NF-κB subunits form homo- or hetero-dimer to exert their functions in DNA binding and 
transcriptional activation. In theory, the 5 NF-κB subunits should form 15 unique homo-
and hetero-dimers. However, only 12 of them have been identified in vivo. The three 
unidentified dimers are RelB/RelB, RelB/c-Rel, and p52/c-Rel57. The dimerization is 
conducted by the dimerization domain of the subunits. Two NF-κB subunits interact with 
each other to form the dimerization surface. Of these, p65 and p50 creates the most stable 
NF-κB dimer interface. The positions of Phe-213 and Asn-200 in p65 are occupied by 
Tyr-269 and Asp-256 in p50 to form a highly stable hydrogen bond. Thus, p65/p50 is the 
most stable and abundant NF-κB dimer in vivo.  
 Studies on the X-ray structures of the NF-κB:DNA complex have revealed the 
interaction between the NF-κB dimer and DNA containing κB sequence. The NF-κB 
dimers form a butterfly-like structure through the dimerization domain, and use both the 
amino-terminal and dimerization domain to encircle the DNA containing κB and activate 




I.4.3 Regulation of NF-κB signaling 
 
There are two distinct NF-κB activation pathways, the canonical pathway and the 
alternative pathway (Fig. 2). The primary NF-κB complex in the canonical pathway is the 
p65/p50 complex, which is sequestered in the cytosol by the bound inhibitor of NF-κB 
(IκBα). Meanwhile, RelB/p100 is the major NF-κB complex in the alternative pathway. 
These two NF-κB pathways are activated by two distinct sets of stimuli, and regulates 
different biological processes. The canonical pathway is activated by antigens, LPS or 
pro-inflammatory cytokines, such as TNFα and IL-1β, which are recognized by antigen 
receptor, Toll-like receptors, or cytokine receptors. The stimuli are further transmitted to 
the IκB kinase (IKK) complex and the major component IKKβ is activated and 
phosphorylated. Then the phosphorylated IKKβ induces the ubiquitin-proteasome-
mediated degradation of the inhibitor of NF-κB (IκBα) through phosphorylating IκBα. 
The active p65/p50 heterodimer then translocates into the nucleus to activate its target 
genes, including genes involved in inflammation, survival, and proliferation.  
 The alternative pathway is stimulated by lymphotoxin, B-cell activating factor 
(BAFF), CD40, OX40, or CD 27. The corresponding receptors then activate the NF-κB 
inducing kinase (NIK), which further induces the activation of the IKKα. Active IKKα 
then phosphorylates p100 at Ser-866 and Ser-870 sites. The phosphorylated p100 is 
processed to p52 via the ubiquitin-proteasome-mediated degradation of its carboxy-
terminus. The RelB/p52 heterodimer then translocates into the nucleus to regulate its 
target genes, including chemokines and genes involved in lymphoid organogenesis.  
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Figure 2. The canonical and alternative NF-κB pathways. 
Canonical pathway is primarily stimulated by pro-inflammatory stimuli, such as LPS, 
TNFα and IL-1β. The activated IKK complex phosphorylates IκBα and induces IκBα 
degradation. The free p65/p50 heterodimer then translocates into the nucleus to regulate 
genes related to inflammation, proliferation, and survival. The alternative pathway is 
closely involved in the lymphoid organogenesis. Lymphotoxin and B-cell activating 
factor activate NIK, which phosphorylates and activated IKKα. Activated IKKα then 
phosphorylates p100, leading the procession of p100 to p52. The RelB/p52 heterodimer 
then translocates into the nucleus to regulate its target genes. 
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 I.5 RhoE and Its Functions in the Heart 
 
I.5.1 The atypical small GTPase RhoE 
 
RhoE belongs to a member of the Rho family of GTPases. RhoE is primarily located in 
the cytosol, and translocates to the cell membrane when farnesylated and 
dephosphorylated58-60. The tissue expression of RhoE is universal while the levels could 
be varied61. RhoE has a unique characteristic in that it lacks GTPase activity and stays in 
the GTP-bound state. Therefore, RhoE is not regulated by GTP/GDP cycling, but instead 
by the expression level and by protein modifications such as prenylation and 
phosphorylation62, 63.  
 The initial function of RhoE is linked to cell actin cytoskeleton dynamics, cell 
migration and apoptosis through the inhibition of its effector, Rho kinase 1 (ROCK1). 
Recent studies have revealed much diversified functions of RhoE in regulation of other 
biological processes, including calcium homeostasis, angiogenesis, cell cycling, 




I.5.2 Study of RhoE in the heart 
 
Compared to RhoE’s roles in tumorigenesis, the functions of RhoE in the heart has been 
less studied. Our lab have revealed a diversified functions of RhoE in the cardiac 
physiology, including cardiomyocyte apoptosis, cardiac angiogenesis, and cardiac 
calcium handling. We found that RhoE expression level is downregulated in the heart of 
patients with end-stage heart failure67.  
 RhoE is essential to suppress ROCK1-mediated cardiomyocyte apoptosis, and 
RhoE deficiency in mouse led to increased apoptotic cardiomyopathy, resulting in higher 
tendency of heart failure after pressure overload by transverse aortic constriction (TAC). 
RhoE also plays an important role in regulating the cardiac angiogenesis in response to 
pressure overload65. RhoE is required to stabilize the hypoxia-inducible factor 1α (HIF-
1α), which is the primary transcription factor of vascular endothelial growth factor 
(VEGF). RhoE deficiency in mouse led to decreased the cardiac VEGF expression and 
impaired angiogenesis. 
 Finally, RhoE is also involved in mediating the cardiac calcium homeostasis64. 
RhoE-null mouse died at the embryonic stage with fetal arrhythmias. Mechanistically, 
depletion of RhoE triggers severe calcium leakage. RhoE deficiency impairs lysosomal 
targeting and degradation of the β2-adrenergic receptor, leading to increased β2-
adrenergic receptor level and hyperactivated protein kinase A (PKA) signaling. PKA 




MATERIALS AND METHODS 
II.1 Animals
The Institutional Animal Care and Use Committee (IACUC) of Texas A&M University 
Health Science Center Institute of Biosciences and Technology approved the experiments 
with animals. The following mouse lines were used in the study: Wild-type (WT) mouse; 
RhoE floxed control (RhoEflox/+) mouse; cardiomyocyte-specific RhoE hyploinsufficient 
(RhoEflox/+;MHC-Cre) mouse; cardiomyocyte-specific RhoE overexpression transgenic 
(RhoE-TG) mouse. 
II.2 Mouse MI Model
Male mice at the age of 12 weeks were used in the MI surgery. Acute myocardial infarction 
was induced as described in the earlier studies as described in our and other earlier 
studies71. In brief, mice were fully anesthetized with 2% isoflurane gas and oxygen. Then 
mice were subject to endotracheal intubation and mechanically ventilated with a rodent 
respirator. Left thoracotomy was performed to open the chest cavity. The heart was then 
exposed and the left anterior descending (LAD) coronary artery was permanently ligated 
with a 6-0 silk suture at the site of about 2 mm lower than the tip of the left auricle. 
Successful LAD ligation was confirmed by appearance of a paler color in the anterior wall 
of the left ventricle. The chest was then closed and post-operative care was given. The 













The following antibodies were used in the experiments (Table 3). 
Table 3 Antibodies used in the experiments.
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II.5 Mammalian Expression Constructs
NF-κB-dependent firefly reporter plasmid and EF1α promoter-dependent Renilla reporter 
plasmid were kindly provided by Dr. Xin Lin (University of Texas MD Anderson Cancer 
Center, USA). Human RhoE cDNA was subcloned into pCMV-myc-N vector (Clontech, 
635689) to generate myc-RhoE expression construct. Human p65 cDNA was subcloned 
into p3xFLAG-CMV (Sigma Aldrich, E4026) to generate flag-p65 expression construct. 
Human p65 cDNA was subcloned into pEGFP-C3 (Clontech) to generate GFP-p65 
expression construct. The truncated mutants of GFP-p65 were generated using Q5 site-
directed mutagenesis kit (New England Biolabs, E0554S). Human p50 cDNA was 
subcloned into pCMV-HA-N (Clontech, 635690) to generate HA-p50 expression 
construct. The truncated mutants of HA-p50 were generated using Q5 site-directed 
mutagenesis kit (New England Biolabs, E0554S). All expression constructs used in the 








II.6 Cell Culture and Transfection 
Mouse C2C12 myoblast cells were obtained from ATCC (CRL-1772) and cultured in 
DMEM medium supplemented with 20% fetal bovine serum. Human embryonic kidney 
HEK293T cells were obtained from ATCC (CRL-11268) and cultured in DMEM medium 
supplemented with 10% fetal bovine serum. The adult mouse cardiomyocytes were 
isolated from adult mouse heart using the isolation kit (Cellutron Life Technologies, ac-
7031). The isolated cardiomyocytes were cultured in AW medium (Cellutron Life 
Technologies, m-8034). 
 The transfections in HEK293T cells were performed using lipofectamine 2000 
transfection reagent (Thermofisher, 11668027). The transfections in C2C12 cells were 
performed using the Neon electroporation system (Thermofisher, MPK10025). siRNA 
was transfected into cells using Lipofectamine RNAiMAX transfection reagent 
(ThrmoFisher, 13778150) 
  
II.7 Dual-luciferase Assay 
Dual-luciferase assay was performed according to our earlier study65. Briefly, C2C12 cells 
were seeded in triplicates in a 12-well plate overnight to reach 70% confluency. The cells 
in each well were transfected with 50 ng of NF-κB-dependent firefly reporter construct 
and 5 ng of Renilla reporter construct together with either 10 pmol of control siRNA or 
10 pmol of RhoE-specific siRNA. 16 hours after the transfection, TNFα was added with 
a final concentration of 40 ng/ml and the cells were harvested 4 hours later. Dual-luciferase 
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activities were measured using the dual-luciferase reporter assay system (Promega, 
E1910). The Renilla luciferase activity was used for the normalization purpose. 
 
II.8 Electrophoretic Mobility Shift Assay (EMSA) 
Nuclear extracts of the C2C12 cells were prepared by NE-PER nuclear and cytoplasmic 
extraction reagents (ThermoFisher, 78833). 10 μg nuclear extracts and 2 μl of 1 μM 32P-
labeled annealed κB probes (5'- AGTTGAGGGGACTTTCCCAGGC-3' and 5'-
GCCTGGGAAAGTCCCCTCAACT-3') were incubated in the binding buffer (50 mM 
HEPES, 100 mM KCl, 2.5 mM MgCl2, 0.25 mM EGTA, 1.25 mM DTT, 0.2 μg/ul poly-
dI-dC) at room temperature for 15 minutes. The samples were separated by a non-
denaturing polyacrylamide gel, and the gel was then dried at 80°C for 2 hours followed 
by the X-ray film detection. 
 
II.9 GST Pull-down Assay 
Human RhoE cDNA was subcloned into pGEX-6P-1 (GE Healthcare) to generate GST-
RhoE construct. GST and GST-RhoE recombinant proteins were expressed in E. coli and 
extracted by glutathione sepharose (GE Healthcare). The proteins were purified by high-
performance liquid chromatography. GST or GST-RhoE protein was conjugated to 
glutathione beads in 1ml of NP-40 lysis buffer followed by the addition of His-p65 or His-





II.10 Immunoprecipitation and Immunoblotting 
For immunoprecipitation, cells were lysed in NP-40 lysis buffer containing 1.0 mM PMSF 
and protease inhibitor cocktail (Roche, 11873580001). The cell lysates were incubated 
with protein G-Sepharose beads (GE Healthcare, 17061801) together with either IgG or 
the specific antibodies at 4°C overnight. The beads were washed with lysis buffer for 4 
times and boiled with 2 x SDS loading buffer (Santa Cruz Biotechnology, sc-24945). The 
samples were separated in 10% Bis-Tris protein gel (ThermoFisher) and transferred to the 
nitrocellulose membrane. The membranes were then incubated with specific primary 
antibodies, following by incubation with the secondary antibody. We used the 
confirmation specific second antibody that only recognized the primary antibody but not 
heavy or light chains of the antibody used for immunoprecipitation. 
 
II.11 Bimolecular Fluorescence Complementation (BiFC) Assay 
The BiFC assay was performed with a modified protocol according to the earlier study72. 
Venus is an improved version of yellow fluorescent protein (YFP). RhoE was subcloned 
into the N-terminus of Venus expression construct; p65 and p50 was cloned into the C-
terminus of Venus individually. C2C12 cells were transfected with different pairs of BiFC 
constructs as indicated in the experiments. 24 hours after the transfection, cells were fixed 






II.12 RNA Isolation and RT-PCR 
Isolation of total RNA from mouse heart was performed using TRIzol reagent (Life 
Technologies, 15596018). cDNAs were synthesized from 1 μg total RNA with the qScript 
One-Step RT-qPCR kit (Quanta Biosciences, 19780). Quantitative RT-PCR was 
performed using SYBR Green PCR Master Mix (Life Technologies, 4309155) in the 
StepOnePlus Real-Time PCR System according to the manufacturer’s instructions. The 


























II.13 Immunohistochemistry (IHC) Staining  
Paraffin sections of the whole heart were used for detecting Ly-6G and F4/80 expression. 
The tissue sections were subjected to antigen retrieval, and then incubated with primary 
antibodies overnight at 4°C, followed by incubation with the HRP-conjugated secondary 
antibody. The pictures were taken by Leica DM2000 histology microscope.  
 
II.14 2, 3, 5-Triphenyltetrazolium Chloride (TTC) Staining 
Three days after myocardial infarction, the mouse heart was isolated and cut in 1.0 mm 
slices. The slices were then incubated with 1% w/v TTC at 37°C for 15 minutes, followed 
by fixation in 10% formalin for 20 minutes.  
 
II.15 Statistical Analysis 
In the two group comparisons, unpaired, 2-tailed student’s t-test was used. All values are 







III.1 RhoE Is a Negative Regulator of Cardiac Inflammation 
 
III.1.1 RhoE deletion upregulates pro-inflammatory factors in the heart 
 
We previously defined the essential roles of RhoE in the cardiac physiology64, 65, 67. RhoE 
is downregulated in human failing heart, and RhoE closely participates in the regulation 
of cardiac ventricular remodeling, calcium handling and cardiac angiogenesis. To further 
explore the cardiac function of RhoE, gene expression profiles of wild-type and RhoE 
knockout mouse E10.5 hearts were analyzed. We observed a significant upregulation of a 
large set of pro-inflammatory factors, including cytokines/chemokines and their 
modulators, members of tumor necrosis factor (TNF) superfamily, interferons, 
immunoreceptors, matrix metalloproteinases (MMPs), etc. (Fig. 3). Since immune cells 
have not been developed at mouse embryonic day 10.573, RhoE deletion-induced elevation 











Figure 3. RhoE deletion upregulates pro-inflammatory factors in embryonic 
mouse heart. 
Heat map represents the expression profile of proinflammatory genes in wild-type 
(WT) and RhoE knockout (KO) embryonic mouse E10.5 hearts. 
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 III.1.2 RhoE deficiency promotes post-MI inflammation 
 
To study the correlation between RhoE and the inflammatory response in the heart, we 
generated RhoE-floxed mouse (Fig. 4A). RhoE-floxed mouse was crossed with αMHC-
Cre transgenic mouse to generate cardiac-specific RhoE haploinsufficient 
(RhoEflox/+;MHC-Cre) mouse. The RhoE deficiency in the heart was examined by western 
blot and deceased RhoE expression was observed (Fig. 4B). The RhoEflox/+;MHC-Cre 
mice were viable and did not show any obvious physical differences compared with the 




   
Figure 4. Generation and validation of cardiac-specific RhoE haploinsufficient 
mouse.  
(A) Schematic diagrams of the targeting strategy for generating mouse with floxed 
RhoE allele.  
(B) Immunoblot to validate RhoE deficiency in the RhoE
flox/+
;MHC-Cre mouse heart. 
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 Acute myocardial infarction surgery was performed in RhoEflox/+;MHC-Cre  and 
RhoEflox/+ mice to induce cardiac acute inflammatory response. The cardiac inflammation 
was then analyzed three days after MI. We observed a significant increase of macrophage 
and neutrophil infiltration in the RhoEflox/+;MHC-Cre mouse hearts compared to the 
RhoEflox/+ mouse hearts (Fig. 5, A and B).  
 Besides the infiltration of inflammatory cells, the production of pro-inflammatory 
cytokines, chemokines and MMPs also represent the severity of inflammatory response. 
We found that RhoE deficiency also promoted the production of pro-inflammatory 
cytokines (IL-1β and TNFα) and MMPs (Fig. 6), indicating excessive inflammation 











;MHC-Cre mouse hearts on day 3 after MI were conducted 
for the Immunohistochemistry staining for the neutrophil marker (Ly-6G) and the 





;MHC-Cre mouse hearts on day 3 after AMI were 





Figure 6. RhoE deficiency promotes post-MI expression of pro-inflammatory 





;MHC-Cre mouse hearts on day 3 after MI were analyzed by 
qRT-PCR for the expression levels of IL-1β, TNFα, MMP2 and MMP9 relative to 
GAPDH.  *: P < 0.05. 
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 Consistent with the excessive cardiac inflammation after acute myocardial 
infarction, enlarged infarct size (Fig. 7A), more deteriorated cardiac function (Fig. 7B), 
and higher mortality rate (Fig. 8) were exhibited in RhoE deficient mice.  
 Collectively, these data suggest that RhoE is required in the heart to restrain post-
MI inflammation, and RhoE deficiency promotes post-MI inflammation, leading to more 




 Figure 7. RhoE deficiency exaggerates AMI-induced cardiac injuries.  
(A) Triphenyltetrazolium chloride (TTC) staining for the infarct size. The infarct areas 
were highlighted by the dashed lines. Scale bar: 1.0 mm.  
(B) Ejection fraction assayed by echocardiography. *: P < 0.05. n: number of the mice 
used for the assessment. 
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Figure 8. RhoE deficiency induces higher mortality in the first week after acute 
myocardial infarction.  




;MHC-Cre mouse in the 
first week post MI. n: number of the mice used for the assessment. 
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III.1.3 Acute myocardial infarction induces RhoE expression 
 
Interestingly, we also observed that acute myocardial infarction induced the expression of 
RhoE in wild-type mouse heart during the first week post myocardial infarction (Fig. 9, A 
and B). RhoE protein level was upregulated during the first week after acute myocardial 
infarction with the peak at day 3, indicating the tight and active participation of RhoE in 







Figure 9. Acute myocardial infarction induces RhoE expression in the heart.  
(A) Wild-type mice were subjected to sham operation or acute myocardial infarction 
surgery. The hearts were collected on day 1, 3, and 7 post myocardial infarction. Heart 
lysates were immunoblotted for RhoE and GAPDH.  
(B) Quantification of immunoblot densities for RhoE relative to GAPDH in (A). 
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III.2 RhoE Negatively Regulates NF-κB Activity 
 
III.2.1 RhoE deficiency promotes NF-κB activation in the heart 
 
NF-κB is one of the most important regulators of inflammatory response in the heart. 
Overaction of NF-κB signaling triggers excessive inflammatory response during the 
cardiac healing process post MI, which contributes to adverse outcomes74-76. Here we 
examined if RhoE modulates post-MI inflammation via NF-κB signaling.  Nuclear p65 
and p50 protein levels were measured to determine the activation of NF-κB in the heart. 
We found that RhoE haploinsufficient (RhoEflox/+;MHC-Cre) mouse showed markedly 
increased NF-κB activation compared to the control (RhoEflox/+) mouse on day 3 post MI 
(Fig. 10A). Overactivation of NF-κB was also revealed in the cardiomyocytes isolated 
from control mouse and RhoE deficient mouse. More nuclear p65 and p50 were observed 
in the isolated RhoE-deficient cardiomyocytes under both resting and TNFα stimulation 
conditions (Fig. 10B), indicating that RhoE deficiency in cardiomyocytes promotes NF-




Figure 10. RhoE deficiency promotes NF-κB activation in the heart and isolated 
cardiomyocyte.  





hearts on day 3 post MI.  





;MHC-Cre mice. The cells were either untreated or stimulated 
with 40 ng/ml of TNFα for 15 minutes. 
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III.2.2 RhoE negatively regulates NF-κB in vitro 
 
To examine whether RhoE is a new regulator of NF-κB, in vitro experiments were 
performed. NF-κB-dependent luciferase reporter assay was used to detect NF-κB activity. 
We found that RhoE knockdown induced about 10-fold increase in the NF-κB-dependent 
reporter luciferase activity (Fig. 11A). The increase was also revealed under TNFα 
stimulation. On the contrary, enforcing RhoE expression led to the opposite result: the 
luciferase activity gradually declined in parallel with incremental increases in the RhoE 
expression level (Fig. 11B). The inhibitory effects of RhoE for NF-κB were also verified 
by the electrophoretic mobility shift assay (EMSA). A strong band-shift of NF-κB-DNA 
complex was observed under RhoE knockdown condition in C2C12 cells (Fig. 12A), 
while an opposite result was detected when RhoE is overexpressed (Fig. 12B). 
Collectively, these in vitro results suggest that RhoE is a new suppressor of NF-κB, which 
is consistent with the results in the post-MI heart and the isolated cardiomyocytes. 
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Figure 11. RhoE negatively regulates NF-κB transcriptional activity.  
(A and B) NF-κB-dependent reporter luciferase assay in C2C12 cells transfected with 
control siRNA or RhoE-specific siRNA (A), and in C2C12 cells transfected with empty 
vector or myc-RhoE expression construct (B). The cells were either untreated or 
stimulated with 40 ng/ml of TNFα for 4 hours. The expression levels of RhoE were 




Figure 12. RhoE negatively regulates NF-κB DNA binding activity.  
(A and B) EMSA assay for NF-κB activity in C2C12 cells transfected with control 
siRNA or RhoE-specific siRNA (A), or in C2C12 cells transfected with empty vector or 




III.3 RhoE Sequesters NF-κB in the Cytosol  
 
III.3.1 RhoE binds to p65 and p50 in GST-pull-down  
 
To study RhoE’s regulatory mechanisms on NF-κB, we assessed the associations of RhoE 
with the NF-κB components: p65 and p50. GST and GST-RhoE recombinant proteins 
were first expressed in E. coli bacterial. The recombinant proteins were released by 
ultrasonication and bound by glutathione sepharose. The recombinant proteins were 
further purified by high-performance liquid chromatography and subsequently used to 
examine the binding with p65 and p50. In vitro GST pull-down showed strong bindings 






Figure 13. RhoE physically binds to p65 and p50 individually.  
(A) In vitro GST pull-down assay of GST and GST-RhoE fusion proteins with His-p65 
fusion protein.  




III.3.2 RhoE binds to p65 and p50 in co-immunoprecipitation  
 
We also performed co-immunoprecipitations to further verify the interaction of RhoE with 
p65 and p50. The HEK293T cells were transfected with myc-RhoE expression construct, 
and the mutual physical interaction of ectopic RhoE with endogenous p65 and p50 were 










Figure 14. Mutual interactions of RhoE with p65 and p50.  
(A and B) Reciprocal immunoprecipitations of overexpressed myc-RhoE with 
endogenous p65 (A) or with endogenous p50 (B) in HEK293T cells.  
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III.3.3 RhoE interacts with p65 and p50 in the cell cytosol 
 
Furthermore, we examined the interaction localization of RhoE with p65 and p50 by 
bimolecular fluorescence complementation (BiFC). BiFC is an imaging technology used 
to visualize protein-protein interaction within a cell. The assay is based on re-formation 
of a functional fluorescent protein when two non-fluorescent fragments are brought 
together by two interacting proteins. The result provides the location and the intensity of 
the interaction between the two proteins77. Here, we fused RhoE to the N-terminus of 
fluorescent protein Venus (termed VN-RhoE); and p65 or p50 to the C-terminus of 
fluorescent protein Venus (termed VC-p65 or VC-p50). The constructs used in the assay 
were listed in Table 6. 
 In the BiFC assay, no fluorescent signal was detected when two non-interactive 
proteins were co-expressed in C2C12 cells, which presented as negative controls (Fig. 15). 
However, clear fluorescent signal was exhibited in cells co-transfected of VN-RhoE and 
VC-p65, or VN-RhoE and VC-p50, further confirming the physical interactions of RhoE 
with p65 and p50, respectively (Fig. 16). Importantly, the fluorescent signal was solely 
detected in the cell cytosol, suggesting that RhoE interacts with p65 and p50 individually 

















Figure 15. Negative controls in the BiFC assay.  
C2C12 cells were co-transfected with a pair of VN-RhoE and VC, VC-p65 and VN, or 










Figure 16. RhoE interacts with p65 and p50 in BiFC assay.  
C2C12 cells were co-transfected with expression constructs of VN-RhoE and VC-p65, 
or VN-RhoE and VC-p50, respectively. 24 hours after transfection, the cell nucleus was 




III.3.4 RhoE does not act upstream of IκBα to regulate NF-κB 
 
Known cytosolic suppressors for NF-κB exert their inhibitory effects mainly through 
stabilizing IκBα, promoting p65 and p50 degradation, inhibiting p65 phosphorylation, and 
blocking NF-κB nuclear translocation78-81. We examined these regulatory mechanisms to 
look for how RhoE suppresses NF-κB in the cytosol. Silencing or enforcing RhoE 
expression did not influence the phosphorylation and degradation of IκBα (Fig. 17, A and 
B), indicating that RhoE does not act in the upstream of IκBα and does not influence the 
stabilization of IκBα. Manipulation of RhoE expression also had no effect on the total 
level of p65 and p50 as well as the phosphorylation level of p65 at Ser536 site (Fig. 17, A 
and B), suggesting that RhoE does not affect p65 and p50 degradation as well as the 





Figure 17. RhoE does not act upstream of IκBα.  
C2C12 cells were transfected with control siRNA or RhoE-specific siRNA (A); and 
empty vector or myc-RhoE expression construct (B). Cells were either untreated or 
stimulated with 40 ng/ml TNFα for 15 minutes. The total lysates were immunoblotted 




III.3.5 RhoE blocks NF-κB nuclear translocation 
 
Then we measured nuclear p65 an p50 protein levels to examine whether RhoE affects 
nuclear translocation of the NF-κB complex. Knockdown of RhoE significantly 
augmented nuclear p65 and p50 protein levels in both resting and TNFα-stimulated C2C12 
cells (Fig. 18A), while overexpression of RhoE effectively reduced nuclear p65 and p50 
(Fig. 18B), suggesting that RhoE functions in the cell cytosol to inhibit the nuclear 
translocation of NF-κB. 
 IκBα is  recognized as the major inhibitor of NF-κB nuclear translocation82. We 
examined if IκBα is responsible for RhoE-mediated inhibition of NF-κB nuclear 
translocation. Knockdown of IκBα augmented nuclear NF-κB as expected (Fig. 19). 
However, overexpression of RhoE remained to attenuate NF-κB nuclear translocation 
under the IκBα knockdown condition (Fig. 19), indicating that RhoE inhibits NF-κB 





Figure 18. RhoE inhibits NF-κB nuclear translocation.  
C2C12 cells were transfected with control siRNA or RhoE-specific siRNA (A), and 
empty vector or myc-RhoE expression construct (B). Cells were either untreated or 
stimulated with 40 ng/ml TNFα for 15 minutes. The nuclear lysates were extracted and 




Figure 19. RhoE inhibits NF-κB nuclear translocation independent of IκBα.  
C2C12 cells were transfected with control siRNA or IκBα-specific siRNA together with 
empty vector or myc-RhoE expression construct. Total lysates were immunoblotted for 




III.4 RhoE Impedes the Heterodimerization of p65 and p50 
 
III.4.1 RhoE binds to p50 on multiple interaction sites 
 
We further identified the critical interaction regions of p50 and p65 with RhoE. A series 
of p50 and p65 truncated mutants were generated for co-immunoprecipitation assay. We 
found that both the N-terminus (1-245 aa) and C-terminus (246-443 aa) of p50 bound to 








  Figure 20. RhoE binds to p50 on multiple interaction sites.  
HEK293T cells were transfected of myc-RhoE expression construct together with HA-
p50, HA-p50 (1-245 aa), or HA-p50 (246-433 aa) expression construct. Co-
immunoprecipitation assay was performed with anti-myc antibody. 
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III.4.2 RhoE binds to the dimerization domain of p65 
 
Next, we examined the interaction region of p65 with RhoE. A series GFP-tagged p65 
mutants were generated and used for co-immunoprecipitation assay (Fig. 21). We found 
that RhoE only bound to p65 N-terminus (1-286 aa) but not to its C-terminus (286-551 aa) 
(Fig. 22). The N-terminus of p65 contains two functional domains, the N-terminal domain 
(NTD, 1-186 aa), responsible for DNA binding activity; and the dimerization domain (DD, 
187-286 aa), required for homo- or hetero-dimerization of p65 with other NF-κB 
subunits83. We found that the dimerization domain, but not the N-terminal domain of p65, 




Figure 21. Schematic of p65 domains and truncated mutants.  





Figure 22. RhoE binds to the dimerization domain of p65.  
HEK293T cells were co-transfected of myc-RhoE expression construct with GFP-




 Furthermore, we generated a series of VC-tagged p65 mutants to visualize the 
interaction between p65 fragments and RhoE in BiFC assay. Consistent with the Co-IP 
results, dimerization domain of p65 was showed to be essential for the interaction with 




Figure 23. RhoE binds to the dimerization domain of p65 in BiFC assay.  
C2C12 cells were co-transfected with VN-RhoE and VC-p65 truncated mutants. 24 
hours after transfection, the cell nucleus was counterstained in blue with DAPI dye. 
Venus and DAPI were examined by confocal fluorescent microscope. 
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III.4.3 RhoE disrupts p65/p50 heterodimer 
 
The dimerization domain of p65 is critical for its dimerization with other NF-κB subunits, 
which is an important step for NF-κB activation83. Thus, the binding of RhoE to the 
dimerization domain of p65 may impede the heterodimerization between p65 and p50. We 
used co-immunoprecipitation assay to determine the level of p65/p50 heterodimer. 
Enforcing RhoE expression led to decrease of p65-bound p50 (Fig. 24A) and p50-bound 
p65 (Fig. 24B). The data therefore suggest that RhoE also disrupt the heterodimerization 









Figure 24. RhoE impede the heterodimerization between p65 and p50.  
(A and B) HEK293T cells were transfected of HA-p50 and flag-p65 expression 
constructs together with empty vector or myc-RhoE expression construct. The 
interaction between p65 and p50 was analyzed by co-immunoprecipitation using anti-
flag (A) or anti-HA (B) antibodies as the immunoprecipitation antibody.  
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III.5 RhoE Overexpression Protects Heart from MI Injury 
 
III.5.1 RhoE overexpression in heart inhibits NF-κB activation 
 
Transgenic mouse with cardiac-specific RhoE overexpression (RhoE-TG) was previously 
generated in our lab65. We took advantage of this gain-of-function genetic mouse to test 
whether upregulation of RhoE could diminish the cardiac inflammation. Decreased 
nuclear p65 and p50 were observed in the isolated cardiomyocytes from RhoE-TG mouse 
compared to wildtype mouse (Fig. 25A). Consistent with this result, RhoE-TG mouse 
showed augmented nuclear NF-κB protein levels in the heart post MI than wild-type 









Figure 25. RhoE overexpression reduces nuclear p65 and p50 in cardiomyocyte 
and post-MI heart. 
(A) Immunoblot for nuclear p65 and p50 in cardiomyocytes isolated from WT and 
RhoE-TG mice. The cells were either untreated or stimulated with 40 ng/ml of TNFα 
for 15 minutes. (B) Immunoblot for nuclear p65 and p50 in heart nuclear lysates from 
WT and RhoE-TG mice on day 3 after MI. 
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III.5.2 RhoE overexpression in heart diminishes post-MI inflammation 
 
The degree of cardiac inflammation in the RhoE-TG mouse was also evaluated on day 3 
post MI. Moderate neutrophil and macrophage infiltration with less production of pro-
inflammatory cytokines (IL-1β and TNFα) and MMPs were observed in the RhoE-TG 
mouse heart compared to the WT mouse heart (Fig. 26 and 27). Furthermore, RhoE-TG 
mouse showed reduced infarct size, better preserved cardiac function, and higher survival 
rate post MI compared to WT mouse (Fig. 28 and 29). Together, these results have 
provided physiological evidence to support RhoE as an endogenous suppressor of NF-кB 




Figure 26. RhoE overexpression diminishes post-MI leukocyte infiltration. 
(A and B) WT and RhoE-TG mouse heart were conducted for the following assays on 
day 3 post MI: immunohistochemistry staining (A) and immunoblot (B) for the 












Figure 27. RhoE overexpression suppresses post-MI expression of cytokines and 
MMPs. 
On day 3 post MI, WT and RhoE-TG mouse heart were analyzed for expression of IL-




Figure 28. RhoE overexpression reduces infarct size and improves cardiac function 
post MI. 
(A) On day 3 post MI, WT and RhoE-TG mouse hearts were analyzed for the infarct 
size by triphenyltetrazollum chloride (TTC) staining. The infarct areas were highlighted 
by the dashed lines. Scale bar: 1.0 mm. 
(B) On day 3 post MI, WT and RhoE-TG mice were analyzed for the cardiac function 





Figure 29. RhoE overexpression improves survival rate post MI. 









Cardiac inflammation in the acute myocardial infarction is a prerequisite for healing and 
repairing of the infarcted myocardium, while tight control and timely suppression of this 
acute inflammatory response is important to restrain from inflammatory injury and 
excessive myocardium degradation19. In this study, RhoE is identified as a negative 
mediator of post-MI inflammation by acting on its upstream regulator, NF-κB. RhoE 
specifically inhibits NF-κB activation through two novel mechanisms: the blockage of 
NF-κB nuclear translocation, and the disruption of p65/p50 heterodimer (Fig. 30). 
Furthermore, RhoE overexpression in the heart protects heart against post-MI 
inflammatory injuries. RhoE, therefore, may provide a new anti-inflammatory target for 






Figure 30. Schematic model for RhoE-mediated regulation of inflammation by 
suppressing NF-κB signaling. 
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IV.2 Role of NF-κB in the Heart 
 
The NF-κB signaling has been indicated to play an important role in multiple pathological 
changes in the cardiovascular diseases84, 85. Here, I will discuss the role of NF-κB in 
ischemic preconditioning, ischemic-reperfusion injury and myocardial infarction.  
 Ischemic preconditioning refers to an experimental technique of short episode of 
ischemia and reperfusion86. Myocardial ischemic preconditioning in the experimental 
animals can be performed following a preconditioning protocol that lasts less than 2 hours 
before sustained ischemia in the anesthetized animals (classical preconditioning or first 
window of myocardial protection)87, 88, or 24 to 72 hours in non-anesthetized animals 
(delayed preconditioning or second window of myocardial protection)89. Both strategies 
significantly reduce the infarct size and improve cardiac function. During the 
preconditioning treatment, increased expression of reactive oxygen species, adenosine, 
purines, and nitric oxide efficiently activates NF-κB90-92.  Importantly, the activation of 
NF-κB is found to be required for the protective effects from preconditioning treatment 
since pharmacological inhibition of NF-κB abolished the beneficial effects in both 
classical and delayed preconditioning treatments93. Cardio-protection by NF-κB activation 
may be caused by NF-κB-mediated upregulation of cardioprotective factors, such as 
inducible cyclooxygenase, inducible nitric oxide synthase, and manganese superoxide 
dismutase94-96. Moreover, preconditioning treatment leads to a reduced NF-κB activation 
after sustained ischemia in the heart, which prevents excessive inflammatory response 
during the sustained myocardial ischemia97.  
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 Myocardial ischemia and reperfusion were proved to effectively activate the NF-
κB signaling98. Though NF-κB activation induces a cardioprotective effect during 
preconditioning, overactivated NF-κB during myocardial ischemia and reperfusion is 
detrimental75, 99. NF-κB induces an excessive inflammation and concomitantly extended 
ischemic injury by promoting the expression of pro-inflammatory cytokines, chemokines, 
leukocyte adhesion molecules, and metalloproteinases. Blockage of NF-κB activation post 
myocardial ischemic injury has been proved to effectively improve the infarct size, cardiac 
function, and ventricular remodeling74, 75, 100, 101.  
 In this study, RhoE is found to negatively regulate NF-κB activation. RhoE 
deficiency in the mouse heart leads to increased NF-κB activation post myocardial 
infarction, on the contrary, RhoE overexpression in the mouse heart attenuates NF-κB 
activation. These results validate the cardioprotective role of RhoE in myocardial 




IV.3 RhoE Negatively Regulates NF-κB Signaling 
 
NF-κB pathway is so closely related to many critical physiological processes that the 
interest of discovering new selective and effective NF-κB suppressors has never faded. 
The prevailing view is that IκB proteins function as the major inhibitor to sequester NF-
κB complex in the cytoplasm in an inactive state. Stimuli activates the IKK complex, 
which triggers the phosphorylation IκBα at Ser48 and subsequent proteasome-mediated 
degradation. Then NF-κB translocates into the nucleus to transcriptionally activate its 
target genes57.  Indeed, most NF-κB regulators exert their effects through affecting this 
canonical IKK-IκB-NF-κB signaling54, 76, 102, 103. Several deubiquitinase (DUB) enzymes, 
for example, down-modulate NF-κB signaling via disrupting the IKK-activating 
complex104. A20 is a deubiquitinase that specifically targets on RIP1 and subsequently 
induces RIP1 degradation. Upregulated A20 reduces RIP1 level and RIP1-mediated IKK 
activating complex level as well, resulting in decreased IKK activation and suppressed 
NF-κB activity105. Furthermore, A20 also targets other IKK activators, including RIP2, 
Malt1 and TRAF6106-108. The cellular zinc finger anti-NF-κB (Cezanne) is another DUB 
enzyme that targeting on RIP1 to negatively modulate NF-κB signaling109. The expression 
of Cezanne is also induced by NF-κB through TNFR pathways, which further provides a 
negative feedback loop to modulate the NF-κB signaling. Cylindromatosis (CYLD) is 
another DUB enzyme that negatively regulates the activators of IKK. CYLD 




 Whether there exist IκB-independent regulators to hold NF-κB in the cytoplasm is 
unknown76, 103. One of our findings is that RhoE inhibits NF-κB nuclear translocation 
independent of IκBα. RhoE sequesters NF-κB in the cytosol through directly interacting 
with p65 and p50 individually in the cytosol. It could be that the binding of RhoE to p65 
and p50 masks their nuclear localization signal (NLS), and thus RhoE-bound p65 and p50 
cannot translocate into the nucleus. Consistent with interpretation, we found RhoE binds 
to p50 at multiple sites; RhoE also binds to p65 dimerization domain, which is close to 
p65 NLS site. Furthermore, recent studies show that the nuclear accumulation of NF-κB 
is also regulated by nuclear degradation of p65 80, 111 and nuclear export of p65 79, 112. Our 
results rule out these possibilities since RhoE has no effect on the expression levels of p65 
and p50. Also, the interactions of RhoE with p65 and p50 occur in the cytosol, so RhoE 
may not act directly on the nuclear export of NF-κB. 
 Termination of NF-κB activity in the nucleus is another important mechanism to 
suppress the NF-κB signaling. IκB proteins can bind to and mediate the export of the 
nuclear NF-κB complex back into the cytosol, resulting in termination of NF-κB 
signaling113. Besides IκB proteins, there also exist some IκB-independent inhibitors that 
terminate NF-κB activity in the nucleus. The E3 ubiquitin ligase PDLIM2, for example, 
induces the degradation of nuclear p65 to suppress the LPS-stimulated NF-κB activity. 
PDLIM2 binds to nuclear p65 through its PDZ domain and subsequently triggers p65 
polyubiquitination. The polyubiquitinated p65 is then targeted by PDLIM2 to discrete 
intracellular compartments for proteasomal degradation80. The COMMD1-Cullin2-
SOCS1 complex is another E3 ligase that promotes degradation of p65 in the nucleus. 
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After TNFα-triggered NF-κB activation and nuclear translocation, COMMD1 bridges 
nuclear p65 to Cullin2 and SOCS1, which mediate the ubiquitination and degradation of 
nuclear p65111. In this study, we also examined whether RhoE modulates p65 degradation. 
However, we did not observe any change in total p65 protein level under RhoE knockdown 
or RhoE overexpression conditions, suggesting that RhoE regulates NF-κB not through 
modulating its degradation. 
 Post-translational modification (PTM) of NF-κB components, such as 
phosphorylation, acetylation and methylation of p65, and microRNA-induced inhibition 
of NF-κB signaling, are also emerging as alternative strategies to eliminate NF-κB 
activity114, 115. Recently, methylation of p65 is reported as an important PTM-regulatory 
mechanism to modulate NF-κB signaling. SETD6 specifically targets on p65 at Lys310 
and induces mono-methylation of Lys310 (p65K310me1)116. Under basal conditions, 
p65K310me1 is recognized by the ankyrin repeat of the histone methyltransferase GLP, 
which induces methylation of H3 Lys9 at NF-κB target genes, resulting in a repressed 
chromatin state. Under stimulated conditions, protein kinase C-ζ (PKC- ζ) phosphorylates 
p65 at Ser311. This PTM modification blocks the binding of GLP to p65K310me1 and 
therefore relieve repression of NF-κB target genes. Furthermore, p65 is phosphorylated 
by protein kinase A (PKAc) at Ser276, which enhances the NF-κB transcriptional 
activity117. Also, Ser536 of p65 is targeted for phosphorylation by IKKs, ribosomal 
subunit kinase-1 (RSK1), and TANK binding kinase (TBK1)118-120. On the contrary, 
GSK3β, IKKβ and IKKε phosphorylate p65 on Ser468, resulting in reduced NF-κB 
transcriptional activity121, 122. The RhoE effector ROCK1 has been reported to be required 
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for NF-κB activation by phosphorylating p65 at Ser 536 123, 124. There is a possibility that 
RhoE negatively regulates NF-κB by the inhibition of ROCK1 activity. However, our 
results show that the phosphorylation level of p65 Ser536 is not affected by RhoE, 
indicating that RhoE exerts its inhibitory effects on NF-κB independent of ROCK1. 
 Assembly of individual subunit of Rel family into homo- and hetero-dimer is a 
critical step in the formation of functional NF-κB complex. p65/p50 heterodimer has been 
proved to be the most stable and abundant NF-κB 57, 125. Heterodimerization of p65 and 
p50 enables p65/p50 heterodimer the DNA binding and transactivation activity. To our 
knowledge, there are few repots about the regulation of p65/p50 heterodimerization. Our 
observations suggest that RhoE also regulates p65/p50 heterodimerization. RhoE binds to 
the dimerization domain of p65 and therefore disrupts the dimerization surface of p65 with 
other NF-κB subunits. Indeed, decreased p65/p50 heterodimer was observed when RhoE 
is upregulated.  
 Collectively, this study demonstrates two regulator mechanisms of RhoE on NF-
κB: 1) RhoE binds to p65 and p50 in the cytosol to block their nuclear translocation; 2) 
RhoE binds to the dimerization region of p65 and subsequently disrupts the 




IV.4 RhoE Protects Heart from Post-infarction Inflammatory Injury 
 
RhoE has been reported as a cardioprotective factor in preventing the apoptotic 
cardiomyopathy, promoting angiogenesis in response to pressure-overload stress, and in 
tightly handling cardiac calcium64, 65, 67. This study identified RhoE as a new negative 
regulator of NF-κB signaling. Since NF-κB is the major inflammatory regulator during 
myocardial infarction. Overactivated NF-κB triggers excessive inflammation, leading to 
expanded ischemic injury. In this study, RhoE deficiency in the heart was found to 
promote NF-κB activation and post-infarction inflammation, resulting in increased infarct 
size and higher mortality. On the contrary, overexpression of RhoE in the heart was able 
to suppress NF-κB activation and diminish post-infarction inflammation. Overexpression 
of RhoE remarkably reduced the infarct size and improved the cardiac function and 





IV.5 Limitations and Future Work 
 
Given the complexity of the negative regulation of inflammatory responses, many 
important questions about RhoE in this study remain to be answered. The limitation of the 
study should be noticed. 
 Multiple cell types are involved in the development of cardia inflammation during 
myocardial infarction, including cardiac resident macrophages, infiltrated neutrophils and 
macrophages, endothelial cells, cardiomyocytes, and cardiac fibroblasts. The present 
study only used cardiomyocyte-specific RhoE deficient or overexpressed mice for the 
investigation of post-infarction inflammation. Though alternation of RhoE expression in 
cardiomyocytes is sufficient to modulate post-infarction inflammation, verification of 
RhoE in different tissues/cells, such as the immune system/cells, with different stimuli is 
necessary and important in future studies.  
 This study only explored the relationship between RhoE and the major NF-κB 
components, p50 and p65. Whether RhoE interacts with its upstream IKK complex is 
unknown. RhoE is also localized to the cell membrane when activated, whether RhoE 
influences the transduction of the NF-κB-stimuli is unclear. 
 Moreover, in this study we observed inhibited NF-κB nuclear translocation by 
RhoE. Though RhoE binds to dimerization domain of p65, which is close to the nuclear 
localization signal (NLS) of p65, it is still unknown whether RhoE could occupy the NLS 
of p65 and subsequently block NF-κB nuclear translocation. The crystal structure of RhoE 
with p65 may reveal more RhoE-p65 interaction information. 
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 The NF-κB activity is also regulated by different post-translational modifications, 
including phosphorylation, acetylation, ubiquitination, and methylation. This study only 
examined the phosphorylation level of p65 at Ser536, which is uninfluenced by RhoE. 
Whether RhoE affects other post-translational modifications are unclear and may need 
further studies.  
 Finally, the NF-κB signaling includes the canonical pathway and alternative 
pathway. Canonical NF-κB pathway primarily regulates the inflammatory responses, 
while alternative NF-κB pathway plays an important role in lymphoid organogenesis and 
overactivated alternative NF-κB pathway promotes lymphatic cancers. Whether RhoE has 
a similar regulatory role in the alternative pathway as in canonical pathway remains 
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